- Home
- GENK vs ATHA Comparison
GENK vs ATHA Comparison
Compare GENK & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- ATHA
- Stock Information
- Founded
- GENK 2011
- ATHA 2011
- Country
- GENK United States
- ATHA United States
- Employees
- GENK N/A
- ATHA N/A
- Industry
- GENK Restaurants
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- GENK Consumer Discretionary
- ATHA Health Care
- Exchange
- GENK Nasdaq
- ATHA Nasdaq
- Market Cap
- GENK 16.3M
- ATHA 18.2M
- IPO Year
- GENK 2023
- ATHA 2020
- Fundamental
- Price
- GENK $2.49
- ATHA $4.47
- Analyst Decision
- GENK Strong Buy
- ATHA
- Analyst Count
- GENK 2
- ATHA 0
- Target Price
- GENK $7.00
- ATHA N/A
- AVG Volume (30 Days)
- GENK 60.5K
- ATHA 26.1K
- Earning Date
- GENK 11-07-2025
- ATHA 11-06-2025
- Dividend Yield
- GENK 1.20%
- ATHA N/A
- EPS Growth
- GENK N/A
- ATHA N/A
- EPS
- GENK N/A
- ATHA N/A
- Revenue
- GENK $217,449,000.00
- ATHA N/A
- Revenue This Year
- GENK $12.35
- ATHA N/A
- Revenue Next Year
- GENK $14.62
- ATHA N/A
- P/E Ratio
- GENK N/A
- ATHA N/A
- Revenue Growth
- GENK 9.36
- ATHA N/A
- 52 Week Low
- GENK $2.31
- ATHA $2.20
- 52 Week High
- GENK $9.04
- ATHA $6.79
- Technical
- Relative Strength Index (RSI)
- GENK 39.21
- ATHA 54.78
- Support Level
- GENK $2.31
- ATHA $4.34
- Resistance Level
- GENK $2.85
- ATHA $4.95
- Average True Range (ATR)
- GENK 0.19
- ATHA 0.35
- MACD
- GENK -0.02
- ATHA -0.04
- Stochastic Oscillator
- GENK 30.99
- ATHA 54.26
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.